Dr. Larry Wray is a member of Virtual Rehab’s Advisory Board.
Dr. Wray has over 30 years of experience in healthcare. He is currently consulting early stage and established companies, universities and non-profit organizations on commercializing new technologies as clinical diagnostic products or research tools.
Prior to his current practice, Dr. Wray most recently was VP, Development at Nanomix, a nanotechnology based point of care diagnostic company and immediately prior to that was VP, R&D for the diagnostics business at PerkinElmer, where he was responsible for a global organization with sites in the U.S., China, and Europe. He has also held leadership positions in R&D, program management, business development, and manufacturing at BayPoint Biosystems (an oncology diagnostic company), Celera (a molecular diagnostic company, now part of Quest), Ventana (a tissue diagnostics company, now part of Roche) and Abbott Diagnostics.
Dr. Wray has been responsible for the launch of products spanning a wide range of technologies and applications, including infectious diseases, oncology, metabolic diseases, prenatal testing and newborn screening. These have involved world-wide launches, requiring approvals by domestic and international regulatory organizations. He has a broad knowledge of established and emerging technologies and products and their integration into health care delivery. In his various roles, he has been a leader in the development of strategies and programs for novel products making a positive impact on improving the care of patients and in preventative medicine.
Dr. Wray was a postdoctoral fellow in human genetics at the University of Pennsylvania School of Medicine. He holds a PhD in genetics from the University of Texas at Austin, a MS in genetics counseling from the University of California, Berkeley and a BA in chemistry from Southern Illinois University at Carbondale.